Ultragenyx Investors Urged to Join Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. for violations of securities laws.

Mar. 30, 2026 at 2:40pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a pair of glasses arranged on a clean, monochromatic background, symbolizing the gravity and importance of a securities fraud lawsuit.A legal case against a pharmaceutical company exposes the high stakes and complex challenges facing investors seeking accountability.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for violations of securities laws. Investors who purchased the company's securities between August 3, 2023 and December 26, 2025 are encouraged to contact the firm before April 6, 2026 to discuss their rights.

Why it matters

The lawsuit alleges that Ultragenyx made false and misleading statements to investors about its understanding of the effects of a drug candidate for Osteogenesis Imperfecta. When the company's failures were revealed in a failed Phase III study, investors suffered losses.

The details

According to the complaint, Ultragenyx gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta (OI). The company's failures were revealed when the Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate (AFR).

  • The class period is from August 3, 2023 to December 26, 2025.
  • Investors must contact the Schall Law Firm before April 6, 2026 to discuss their rights.

The players

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company that develops therapies for rare and ultra-rare genetic diseases.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Brian Schall

An attorney at the Schall Law Firm who is encouraging investors to contact the firm to discuss their rights.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm

What’s next

The judge in the case will decide on April 6, 2026 whether to certify the class action lawsuit.

The takeaway

This case highlights the importance of pharmaceutical companies being transparent and accurate in their communications with investors, especially regarding the development and performance of their drug candidates. Investors who suffered losses due to Ultragenyx's alleged misconduct may be able to recover those losses by joining the class action lawsuit.